APO Research
Talk to an analyst

APO RESEARCH · REPORT

Retinal Drugs and Biologics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Retinal Drugs and Biologics Market Outlook and Growth Opportunities 2026

22 December 2025190 pages

Choose your research edition.

Industry ResearchRetinal Drugs and Biologics Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Retinal Drugs and Biologics Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Retinal Drugs and Biologics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Retinal Drugs and Biologics Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Retinal Drugs and Biologics Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Retinal Drugs and Biologics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Retinal Drugs and Biologics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Retinal Drugs and Biologics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Retinal Drugs and Biologics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Retinal Drugs and Biologics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Retinal Drugs and Biologics market include ALLERGAN, Alimera Sciences, Bausch & Lomb, Bristol-Myers Squibb, Genentech, Genzyme, Janssen Biotech, OCULAR THERAPEUTIX and Swedish Orphan Biovitrum, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Retinal Drugs and Biologics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Retinal Drugs and Biologics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Retinal Drugs and Biologics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Retinal Drugs and Biologics market size, projected growth trends, production technologies, key applications, and end-use industries.

Retinal Drugs and Biologics Segment by Company

ALLERGAN

Alimera Sciences

Bausch & Lomb

Bristol-Myers Squibb

Genentech

Genzyme

Janssen Biotech

OCULAR THERAPEUTIX

Swedish Orphan Biovitrum

UCBCares

AbbVie

Roche

Retinal Drugs and Biologics Segment by Type

Ocular Inflammatory Disease (Uveitis)

Diabetic Retinopathy

Age Related Macular Degeneration

Macular Hole

Retinal Drugs and Biologics Segment by Application

Hospitals

Clinics

Others

Retinal Drugs and Biologics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Retinal Drugs and Biologics status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Retinal Drugs and Biologics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Retinal Drugs and Biologics significant trends, drivers, influence factors in global and regions.

6. To analyze Retinal Drugs and Biologics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Retinal Drugs and Biologics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Retinal Drugs and Biologics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Retinal Drugs and Biologics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Retinal Drugs and Biologics market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Retinal Drugs and Biologics industry.

Chapter 3: Detailed analysis of Retinal Drugs and Biologics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Retinal Drugs and Biologics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Retinal Drugs and Biologics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Retinal Drugs and Biologics Industry Trends Table 2. Retinal Drugs and Biologics Industry Drivers Table 3. Retinal Drugs and Biologics Industry Opportunities and Challenges Table 4. Retinal Drugs and Biologics Industry Restraints Table 5. Global Retinal Drugs and Biologics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Retinal Drugs and Biologics Revenue Share by Company (2021-2026) Table 7. Global Retinal Drugs and Biologics Sales Volume by Company (k tons) & (2021-2026) Table 8. Global Retinal Drugs and Biologics Sales Volume Share by Company (2021-2026) Table 9. Global Retinal Drugs and Biologics Average Price (US$/ton) of Company (2021-2026) Table 10. Global Retinal Drugs and Biologics Company Ranking, (2024-2026) & (USD Million) Table 11. Global Retinal Drugs and Biologics Key Company Manufacturing Base & Headquarters Table 12. Global Retinal Drugs and Biologics Company, Product Type & Application Table 13. Global Retinal Drugs and Biologics Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Retinal Drugs and Biologics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Ocular Inflammatory Disease (Uveitis) Table 18. Significant Companies of Diabetic Retinopathy Table 19. Significant Companies of Age Related Macular Degeneration Table 20. Significant Companies of Macular Hole Table 21. Global Retinal Drugs and Biologics Sales Volume by Type 2021 VS 2025 VS 2032 (k tons) Table 22. Global Retinal Drugs and Biologics Sales Volume by Type (2021-2026) & (k tons) Table 23. Global Retinal Drugs and Biologics Sales Volume by Type (2027-2032) & (k tons) Table 24. Global Retinal Drugs and Biologics Sales Volume Share by Type (2021-2026) Table 25. Global Retinal Drugs and Biologics Sales Volume Share by Type (2027-2032) Table 26. Global Retinal Drugs and Biologics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Retinal Drugs and Biologics Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Retinal Drugs and Biologics Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Retinal Drugs and Biologics Sales Value Share by Type (2021-2026) Table 30. Global Retinal Drugs and Biologics Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospitals Table 32. Significant Companies of Clinics Table 33. Significant Companies of Others Table 34. Global Retinal Drugs and Biologics Sales Volume by Application 2021 VS 2025 VS 2032 (k tons) Table 35. Global Retinal Drugs and Biologics Sales Volume by Application (2021-2026) & (k tons) Table 36. Global Retinal Drugs and Biologics Sales Volume by Application (2027-2032) & (k tons) Table 37. Global Retinal Drugs and Biologics Sales Volume Share by Application (2021-2026) Table 38. Global Retinal Drugs and Biologics Sales Volume Share by Application (2027-2032) Table 39. Global Retinal Drugs and Biologics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Retinal Drugs and Biologics Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Retinal Drugs and Biologics Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Retinal Drugs and Biologics Sales Value Share by Application (2021-2026) Table 43. Global Retinal Drugs and Biologics Sales Value Share by Application (2027-2032) Table 44. Global Retinal Drugs and Biologics Sales by Region: 2021 VS 2025 VS 2032 (k tons) Table 45. Global Retinal Drugs and Biologics Sales by Region (2021-2026) & (k tons) Table 46. Global Retinal Drugs and Biologics Sales Market Share by Region (2021-2026) Table 47. Global Retinal Drugs and Biologics Sales by Region (2027-2032) & (k tons) Table 48. Global Retinal Drugs and Biologics Sales Market Share by Region (2027-2032) Table 49. Global Retinal Drugs and Biologics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Retinal Drugs and Biologics Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Retinal Drugs and Biologics Sales Value Share by Region (2021-2026) Table 52. Global Retinal Drugs and Biologics Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Retinal Drugs and Biologics Sales Value Share by Region (2027-2032) Table 54. Global Retinal Drugs and Biologics Market Average Price (US$/ton) by Region (2021-2026) Table 55. Global Retinal Drugs and Biologics Market Average Price (US$/ton) by Region (2027-2032) Table 56. Global Retinal Drugs and Biologics Sales by Country: 2021 VS 2025 VS 2032 (k tons) Table 57. Global Retinal Drugs and Biologics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Retinal Drugs and Biologics Sales by Country (2021-2026) & (k tons) Table 59. Global Retinal Drugs and Biologics Sales Market Share by Country (2021-2026) Table 60. Global Retinal Drugs and Biologics Sales by Country (2027-2032) & (k tons) Table 61. Global Retinal Drugs and Biologics Sales Market Share by Country (2027-2032) Table 62. Global Retinal Drugs and Biologics Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Retinal Drugs and Biologics Sales Value Market Share by Country (2021-2026) Table 64. Global Retinal Drugs and Biologics Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Retinal Drugs and Biologics Sales Value Market Share by Country (2027-2032) Table 66. ALLERGAN Company Information Table 67. ALLERGAN Business Overview Table 68. ALLERGAN Retinal Drugs and Biologics Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 69. ALLERGAN Retinal Drugs and Biologics Product Portfolio Table 70. ALLERGAN Recent Development Table 71. Alimera Sciences Company Information Table 72. Alimera Sciences Business Overview Table 73. Alimera Sciences Retinal Drugs and Biologics Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 74. Alimera Sciences Retinal Drugs and Biologics Product Portfolio Table 75. Alimera Sciences Recent Development Table 76. Bausch & Lomb Company Information Table 77. Bausch & Lomb Business Overview Table 78. Bausch & Lomb Retinal Drugs and Biologics Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 79. Bausch & Lomb Retinal Drugs and Biologics Product Portfolio Table 80. Bausch & Lomb Recent Development Table 81. Bristol-Myers Squibb Company Information Table 82. Bristol-Myers Squibb Business Overview Table 83. Bristol-Myers Squibb Retinal Drugs and Biologics Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 84. Bristol-Myers Squibb Retinal Drugs and Biologics Product Portfolio Table 85. Bristol-Myers Squibb Recent Development Table 86. Genentech Company Information Table 87. Genentech Business Overview Table 88. Genentech Retinal Drugs and Biologics Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 89. Genentech Retinal Drugs and Biologics Product Portfolio Table 90. Genentech Recent Development Table 91. Genzyme Company Information Table 92. Genzyme Business Overview Table 93. Genzyme Retinal Drugs and Biologics Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 94. Genzyme Retinal Drugs and Biologics Product Portfolio Table 95. Genzyme Recent Development Table 96. Janssen Biotech Company Information Table 97. Janssen Biotech Business Overview Table 98. Janssen Biotech Retinal Drugs and Biologics Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 99. Janssen Biotech Retinal Drugs and Biologics Product Portfolio Table 100. Janssen Biotech Recent Development Table 101. OCULAR THERAPEUTIX Company Information Table 102. OCULAR THERAPEUTIX Business Overview Table 103. OCULAR THERAPEUTIX Retinal Drugs and Biologics Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 104. OCULAR THERAPEUTIX Retinal Drugs and Biologics Product Portfolio Table 105. OCULAR THERAPEUTIX Recent Development Table 106. Swedish Orphan Biovitrum Company Information Table 107. Swedish Orphan Biovitrum Business Overview Table 108. Swedish Orphan Biovitrum Retinal Drugs and Biologics Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 109. Swedish Orphan Biovitrum Retinal Drugs and Biologics Product Portfolio Table 110. Swedish Orphan Biovitrum Recent Development Table 111. UCBCares Company Information Table 112. UCBCares Business Overview Table 113. UCBCares Retinal Drugs and Biologics Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 114. UCBCares Retinal Drugs and Biologics Product Portfolio Table 115. UCBCares Recent Development Table 116. AbbVie Company Information Table 117. AbbVie Business Overview Table 118. AbbVie Retinal Drugs and Biologics Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 119. AbbVie Retinal Drugs and Biologics Product Portfolio Table 120. AbbVie Recent Development Table 121. Roche Company Information Table 122. Roche Business Overview Table 123. Roche Retinal Drugs and Biologics Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 124. Roche Retinal Drugs and Biologics Product Portfolio Table 125. Roche Recent Development Table 126. Key Raw Materials Table 127. Raw Materials Key Suppliers Table 128. Retinal Drugs and Biologics Distributors List Table 129. Retinal Drugs and Biologics Customers List Table 130. Research Programs/Design for This Report Table 131. Authors List of This Report Table 132. Secondary Sources Table 133. Primary Sources List of Figures Figure 1. Retinal Drugs and Biologics Product Image Figure 2. Global Retinal Drugs and Biologics Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Retinal Drugs and Biologics Sales Value (2021-2032) & (US$ Million) Figure 4. Global Retinal Drugs and Biologics Sales (2021-2032) & (k tons) Figure 5. Global Retinal Drugs and Biologics Sales Average Price (US$/ton) & (2021-2032) Figure 6. Global Retinal Drugs and Biologics Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Ocular Inflammatory Disease (Uveitis) Image Figure 10. Diabetic Retinopathy Image Figure 11. Age Related Macular Degeneration Image Figure 12. Macular Hole Image Figure 13. Global Retinal Drugs and Biologics Sales Volume by Type (2021 VS 2025 VS 2032) & (k tons) Figure 14. Global Retinal Drugs and Biologics Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Retinal Drugs and Biologics Sales Volume Share by Type (2021-2032) Figure 16. Global Retinal Drugs and Biologics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Retinal Drugs and Biologics Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Retinal Drugs and Biologics Sales Value Share by Type (2021-2032) Figure 19. Hospitals Image Figure 20. Clinics Image Figure 21. Others Image Figure 22. Global Retinal Drugs and Biologics Sales Volume by Application (2021 VS 2025 VS 2032) & (k tons) Figure 23. Global Retinal Drugs and Biologics Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Retinal Drugs and Biologics Sales Volume Share by Application (2021-2032) Figure 25. Global Retinal Drugs and Biologics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Retinal Drugs and Biologics Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Retinal Drugs and Biologics Sales Value Share by Application (2021-2032) Figure 28. Global Retinal Drugs and Biologics Sales by Region: 2021 VS 2025 VS 2032 (k tons) Figure 29. Global Retinal Drugs and Biologics Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Retinal Drugs and Biologics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Retinal Drugs and Biologics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Retinal Drugs and Biologics Sales Value (2021-2032) & (US$ Million) Figure 33. North America Retinal Drugs and Biologics Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Retinal Drugs and Biologics Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Retinal Drugs and Biologics Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Retinal Drugs and Biologics Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Retinal Drugs and Biologics Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Retinal Drugs and Biologics Sales Value (2021-2032) & (US$ Million) Figure 39. South America Retinal Drugs and Biologics Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Retinal Drugs and Biologics Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Retinal Drugs and Biologics Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Retinal Drugs and Biologics Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Retinal Drugs and Biologics Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Ocular Inflammatory Disease (Uveitis)
  • Diabetic Retinopathy
  • Age Related Macular Degeneration
  • Macular Hole
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • ALLERGAN
  • Alimera Sciences
  • Bausch & Lomb
  • Bristol-Myers Squibb
  • Genentech
  • Genzyme
  • Janssen Biotech
  • OCULAR THERAPEUTIX
  • Swedish Orphan Biovitrum
  • UCBCares
  • AbbVie
  • Roche

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Retinal Drugs and Biologics Sales Value (2021-2032)
  4. 1.2.2 Global Retinal Drugs and Biologics Sales Volume (2021-2032)
  5. 1.2.3 Global Retinal Drugs and Biologics Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Retinal Drugs and Biologics Market Dynamics
  1. 2.1 Retinal Drugs and Biologics Industry Trends
  2. 2.2 Retinal Drugs and Biologics Industry Drivers
  3. 2.3 Retinal Drugs and Biologics Industry Opportunities and Challenges
  4. 2.4 Retinal Drugs and Biologics Industry Restraints
3 Retinal Drugs and Biologics Market by Company
  1. 3.1 Global Retinal Drugs and Biologics Company Revenue Ranking in 2025
  2. 3.2 Global Retinal Drugs and Biologics Revenue by Company (2021-2026)
  3. 3.3 Global Retinal Drugs and Biologics Sales Volume by Company (2021-2026)
  4. 3.4 Global Retinal Drugs and Biologics Average Price by Company (2021-2026)
  5. 3.5 Global Retinal Drugs and Biologics Company Ranking (2024-2026)
  6. 3.6 Global Retinal Drugs and Biologics Company Manufacturing Base and Headquarters
  7. 3.7 Global Retinal Drugs and Biologics Company Product Type and Application
  8. 3.8 Global Retinal Drugs and Biologics Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Retinal Drugs and Biologics Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Retinal Drugs and Biologics Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Retinal Drugs and Biologics Market by Type
  1. 4.1 Retinal Drugs and Biologics Type Introduction
  2. 4.1.1 Ocular Inflammatory Disease (Uveitis)
  3. 4.1.2 Diabetic Retinopathy
  4. 4.1.3 Age Related Macular Degeneration
  5. 4.1.4 Macular Hole
  6. 4.2 Global Retinal Drugs and Biologics Sales Volume by Type
  7. 4.2.1 Global Retinal Drugs and Biologics Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Retinal Drugs and Biologics Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Retinal Drugs and Biologics Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Retinal Drugs and Biologics Sales Value by Type
  11. 4.3.1 Global Retinal Drugs and Biologics Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Retinal Drugs and Biologics Sales Value by Type (2021-2032)
  13. 4.3.3 Global Retinal Drugs and Biologics Sales Value Share by Type (2021-2032)
5 Retinal Drugs and Biologics Market by Application
  1. 5.1 Retinal Drugs and Biologics Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Retinal Drugs and Biologics Sales Volume by Application
  6. 5.2.1 Global Retinal Drugs and Biologics Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Retinal Drugs and Biologics Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Retinal Drugs and Biologics Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Retinal Drugs and Biologics Sales Value by Application
  10. 5.3.1 Global Retinal Drugs and Biologics Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Retinal Drugs and Biologics Sales Value by Application (2021-2032)
  12. 5.3.3 Global Retinal Drugs and Biologics Sales Value Share by Application (2021-2032)
6 Retinal Drugs and Biologics Regional Sales and Value Analysis
  1. 6.1 Global Retinal Drugs and Biologics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Retinal Drugs and Biologics Sales by Region (2021-2032)
  3. 6.2.1 Global Retinal Drugs and Biologics Sales by Region: 2021-2026
  4. 6.2.2 Global Retinal Drugs and Biologics Sales by Region (2027-2032)
  5. 6.3 Global Retinal Drugs and Biologics Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Retinal Drugs and Biologics Sales Value by Region (2021-2032)
  7. 6.4.1 Global Retinal Drugs and Biologics Sales Value by Region: 2021-2026
  8. 6.4.2 Global Retinal Drugs and Biologics Sales Value by Region (2027-2032)
  9. 6.5 Global Retinal Drugs and Biologics Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Retinal Drugs and Biologics Sales Value (2021-2032)
  12. 6.6.2 North America Retinal Drugs and Biologics Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Retinal Drugs and Biologics Sales Value (2021-2032)
  15. 6.7.2 Europe Retinal Drugs and Biologics Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Retinal Drugs and Biologics Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Retinal Drugs and Biologics Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Retinal Drugs and Biologics Sales Value (2021-2032)
  21. 6.9.2 South America Retinal Drugs and Biologics Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Retinal Drugs and Biologics Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Retinal Drugs and Biologics Sales Value Share by Country, 2025 VS 2032
7 Retinal Drugs and Biologics Country-level Sales and Value Analysis
  1. 7.1 Global Retinal Drugs and Biologics Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Retinal Drugs and Biologics Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Retinal Drugs and Biologics Sales by Country (2021-2032)
  4. 7.3.1 Global Retinal Drugs and Biologics Sales by Country (2021-2026)
  5. 7.3.2 Global Retinal Drugs and Biologics Sales by Country (2027-2032)
  6. 7.4 Global Retinal Drugs and Biologics Sales Value by Country (2021-2032)
  7. 7.4.1 Global Retinal Drugs and Biologics Sales Value by Country (2021-2026)
  8. 7.4.2 Global Retinal Drugs and Biologics Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Retinal Drugs and Biologics Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Retinal Drugs and Biologics Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Retinal Drugs and Biologics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 ALLERGAN
  2. 8.1.1 ALLERGAN Company Information
  3. 8.1.2 ALLERGAN Business Overview
  4. 8.1.3 ALLERGAN Retinal Drugs and Biologics Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 ALLERGAN Retinal Drugs and Biologics Product Portfolio
  6. 8.1.5 ALLERGAN Recent Developments
  7. 8.2 Alimera Sciences
  8. 8.2.1 Alimera Sciences Company Information
  9. 8.2.2 Alimera Sciences Business Overview
  10. 8.2.3 Alimera Sciences Retinal Drugs and Biologics Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Alimera Sciences Retinal Drugs and Biologics Product Portfolio
  12. 8.2.5 Alimera Sciences Recent Developments
  13. 8.3 Bausch & Lomb
  14. 8.3.1 Bausch & Lomb Company Information
  15. 8.3.2 Bausch & Lomb Business Overview
  16. 8.3.3 Bausch & Lomb Retinal Drugs and Biologics Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Bausch & Lomb Retinal Drugs and Biologics Product Portfolio
  18. 8.3.5 Bausch & Lomb Recent Developments
  19. 8.4 Bristol-Myers Squibb
  20. 8.4.1 Bristol-Myers Squibb Company Information
  21. 8.4.2 Bristol-Myers Squibb Business Overview
  22. 8.4.3 Bristol-Myers Squibb Retinal Drugs and Biologics Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb Retinal Drugs and Biologics Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb Recent Developments
  25. 8.5 Genentech
  26. 8.5.1 Genentech Company Information
  27. 8.5.2 Genentech Business Overview
  28. 8.5.3 Genentech Retinal Drugs and Biologics Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Genentech Retinal Drugs and Biologics Product Portfolio
  30. 8.5.5 Genentech Recent Developments
  31. 8.6 Genzyme
  32. 8.6.1 Genzyme Company Information
  33. 8.6.2 Genzyme Business Overview
  34. 8.6.3 Genzyme Retinal Drugs and Biologics Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Genzyme Retinal Drugs and Biologics Product Portfolio
  36. 8.6.5 Genzyme Recent Developments
  37. 8.7 Janssen Biotech
  38. 8.7.1 Janssen Biotech Company Information
  39. 8.7.2 Janssen Biotech Business Overview
  40. 8.7.3 Janssen Biotech Retinal Drugs and Biologics Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Janssen Biotech Retinal Drugs and Biologics Product Portfolio
  42. 8.7.5 Janssen Biotech Recent Developments
  43. 8.8 OCULAR THERAPEUTIX
  44. 8.8.1 OCULAR THERAPEUTIX Company Information
  45. 8.8.2 OCULAR THERAPEUTIX Business Overview
  46. 8.8.3 OCULAR THERAPEUTIX Retinal Drugs and Biologics Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 OCULAR THERAPEUTIX Retinal Drugs and Biologics Product Portfolio
  48. 8.8.5 OCULAR THERAPEUTIX Recent Developments
  49. 8.9 Swedish Orphan Biovitrum
  50. 8.9.1 Swedish Orphan Biovitrum Company Information
  51. 8.9.2 Swedish Orphan Biovitrum Business Overview
  52. 8.9.3 Swedish Orphan Biovitrum Retinal Drugs and Biologics Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Swedish Orphan Biovitrum Retinal Drugs and Biologics Product Portfolio
  54. 8.9.5 Swedish Orphan Biovitrum Recent Developments
  55. 8.10 UCBCares
  56. 8.10.1 UCBCares Company Information
  57. 8.10.2 UCBCares Business Overview
  58. 8.10.3 UCBCares Retinal Drugs and Biologics Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 UCBCares Retinal Drugs and Biologics Product Portfolio
  60. 8.10.5 UCBCares Recent Developments
  61. 8.11 AbbVie
  62. 8.11.1 AbbVie Company Information
  63. 8.11.2 AbbVie Business Overview
  64. 8.11.3 AbbVie Retinal Drugs and Biologics Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 AbbVie Retinal Drugs and Biologics Product Portfolio
  66. 8.11.5 AbbVie Recent Developments
  67. 8.12 Roche
  68. 8.12.1 Roche Company Information
  69. 8.12.2 Roche Business Overview
  70. 8.12.3 Roche Retinal Drugs and Biologics Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Roche Retinal Drugs and Biologics Product Portfolio
  72. 8.12.5 Roche Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Retinal Drugs and Biologics Value Chain Analysis
  2. 9.1.1 Retinal Drugs and Biologics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Retinal Drugs and Biologics Sales Mode & Process
  6. 9.2 Retinal Drugs and Biologics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Retinal Drugs and Biologics Distributors
  9. 9.2.3 Retinal Drugs and Biologics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst